<DOC>
	<DOCNO>NCT02162914</DOCNO>
	<brief_summary>The study multicenter randomize ( 1:1 ) placebo-controlled , double-blinded phase II trial aim demonstrate improvement median PFS treat locally advance unresectable metastatic patient suffer intra-hepatic hilum ( mass-forming ) cholangiocarcinoma Regorafenib compare placebo , progression GEM-CDDP ( GEM-OX ) , gemcitabine alone follow precede platinum ( CDDP oxaliplatin ) -based chemotherapy . The principal objective investigate Regorafenib efficacy prospectively evaluate PFS administration Regorafenib combine BSC compare placebo BSC . Hypothesis 50 % improvement median PFS ( 6 week 12 week Regorafenib group ) .</brief_summary>
	<brief_title>Regorafenib Versus Placebo Treat Cholangiocarcinoma</brief_title>
	<detailed_description>The principal objective investigate Regorafenib efficacy prospectively evaluate PFS administration Regorafenib combine BSC compare placebo BSC . Hypothesis 50 % improvement median PFS ( 6 week 12 week Regorafenib group ) .</detailed_description>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<criteria>histologically prove intrahepatic hilum cholangiocarcinoma ( mass forming , `` liniting '' tumor ) , locally advance unresectable metastatic progression document GEMCDDP ( GEMOX ) , gemcitabine alone follow precede platinumbased ( CDDP oxaliplatin ) chemotherapy age &gt; 18 year ECOG PS 0/1 study entry measurable disease accord RECIST version 1.1 Adequate bone marrow , liver renal function assess follow laboratory requirementsconducted within 7 day start study treatment : oSerum creatinine &lt; 1.5x upper reference range oTotal bilirubin &lt; 1.5x ULN oAlanine transaminase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5x ULN ( &lt; 5x ULN forpatients liver involvement cancer ) . oAmylase lipase &lt; 1.5x ULN . life expectancy least 12 week effective contraception male female patient risk conception exists negative proteinuria dipstick 24 hour proteinuria &lt; 1000mg sign write informed consent unability take oral medication malabsorption condition patient take strong cytochrome P ( CYP ) CYP3A4 inhibitor ( eg . Clarithromycin , indinavir , itraconazole , ketoconazole , nefazodone , nelfinavir , posaconazole , ritonavir , saquinavir , telithromycin , voriconazole ) strong CYP3A4 inducer ( eg . Carbamazepine , phenobarbital , phenytoin , rifampin , StJohn 's Wort ) ( see section 8 ) persistent proteinuria &gt; 3.5g/24 hour measure urine proteincreatinine ratio random urinesample ( persistent proteinuria &gt; 3 nonhealing woud , ulcer , bone fracture hemorrhage bleed event ≥ CTCAE Grade 3 within 4 week prior start studymedication interstitial lund disease ongoing sign symptoms time informed consent uncontrolled concurrent CNS , cardiac , infectious disease , hypertension history myocardial infarction , deep venous arterial thrombosis , cerebrovascular accident ( CVA ) last 6 month previous exposure antiVEGF target therapy ( include Regorafenib ) signal transduction inhibitor know hypersensitivity component study treatment previous malignancy last past 5 year except basal cell cancer skin preinvasive cancer cervix pregnant lactate woman , patient gender procreative potential use adequate contraceptive method medical psychological condition would permit patient complete study sign inform consent unstable angina , congestive heart failure ≥NYHA class II uncontrolled hypertension despite optimal management ( systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90mmHg ) pheochromocytoma HIV infection active chronic hepatitis B C need antiviral treatment liver failure , cirrhosis Chil Pugh B C brain metastasis major surgery , open biopsy significant traumatic injury within 4 week prior first dose treatment intrahepatic locoregional therapy ( DC Beads , SIRT ) history organ allograft ongoing infection renal failure require dialysis patient receive receive investigational treatment within 4 week prior study entry , participate another clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Intra-hepatic</keyword>
	<keyword>Hilar</keyword>
	<keyword>Locally Advanced</keyword>
	<keyword>Non Resectable</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Regorafenib</keyword>
	<keyword>Placebo</keyword>
</DOC>